ACTU

Actuate Therapeutics, Inc. Common stock
ACTU

$8.27

1.47%

Market Cap: $158M

About: Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3β, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.

–

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for ACTU.

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about ACTU published over the past 30 days

Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma

CHICAGO and FORT WORTH, Texas, Sept. 09, 2024 (GLOBE NEWSWIRE) -- – Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), provided an update on its Phase 1/2 trial of elraglusib in relapsed/refractory Ewing Sarcoma (r/r EWS).

$Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma$

Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference

CHICAGO and FORT WORTH, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, including pancreatic cancer and Ewing sarcoma, through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that it will present at the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024 in New York City. In addition, the management team will be available for one-on-one meetings during the conference.

Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference

U.S. IPO Weekly Recap: WeRide Reschedules While 6 New Filers Join The Pipeline

This week was another slow week for pricings, with two companies making their public debut, along with three SPACs. On the filing side, offshore-focused drilling equipment and aftermarket service provider, HMH Holding, filed to raise $100 million. Three IPOs are currently scheduled to list in the week ahead, all based in the Asia Pacific region. One SPAC is also expected to price.

U.S. IPO Weekly Recap: WeRide Reschedules While 6 New Filers Join The Pipeline

Actuate Therapeutics Announces Closing of Initial Public Offering

CHICAGO and FORT WORTH, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Nasdaq: ACTU) (the “Company”), a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers, announced today the closing of its previously announced initial public offering of 2,800,000 shares of its common stock, at a price of $8.00 per share to the public for a total of $22,400,000 of gross proceeds to the Company, before deducting underwriting discounts and offering expenses (the “Offering”). In addition, the Company has granted a 30-day option to the underwriters to purchase up to 420,000 additional shares, representing 15% of the shares sold in the Offering, solely to cover over-allotments, if any, at the initial public offering price, less the underwriting discounts and commissions. All of the shares are being offered by the Company. The shares began trading on August 13, 2024 on the Nasdaq Global Market under the symbol “ACTU.”

Actuate Therapeutics Announces Closing of Initial Public Offering

Actuate Therapeutics Announces Pricing of Initial Public Offering

CHICAGO and FORT WORTH, Texas, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Nasdaq: ACTU) (the “Company”), a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers, announced today the pricing of its initial public offering of 2,800,000 shares of its common stock, at a price of $8.00 per share to the public for a total of $22,400,000 of gross proceeds to the Company, before deducting underwriting discounts and offering expenses (the “Offering”).

Actuate Therapeutics Announces Pricing of Initial Public Offering

U.S. IPO Weekly Recap: August Kicks Off With One Small Pricing

U.S. IPO Weekly Recap: August Kicks Off With One Small Pricing

U.S. IPO Weekly Recap: August Kicks Off With One Small Pricing

U.S. IPO Weekly Recap: Insurance And Healthcare Lead A 4 IPO Week

A handful of IPOs priced this past week, led by three sizable names. One large issuer joined both the pipeline and the calendar - Chile-based LATAM Airlines Group. Six IPOs are scheduled to list in the week ahead and are set to raise a combined $5.1 billion, the most for any week so far this year. One SPAC is also set to debut.

U.S. IPO Weekly Recap: Insurance And Healthcare Lead A 4 IPO Week

Actuate Therapeutics Seeks IPO For Promising Pancreatic Cancer Drugs

Actuate Therapeutics, Inc. has filed for a $50 million IPO to raise funds for its treatments for pancreatic cancer and other cancer conditions. The global market for pancreatic cancer treatment is forecasted to reach $4.2 billion by 2025, driving the potential growth for Actuate Therapeutics. The company's lead program, elraglusib, has shown promising initial efficacy results in Phase 2 trials.

Actuate Therapeutics Seeks IPO For Promising Pancreatic Cancer Drugs

See News Rankings